Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Banyu Pharmaceutical Co. Ltd

Raymond E Gibson

H Donald Burns

Terence G Hamill

Wai-Si Eng

William K Hagmann

Mark T Goulet

Takehiro Fukami

Ping Liu

Linus S Lin

James Patrick Jewell

Hugh D Burns

Andrey V Peresypkin

Alex Minhua Chen

Howard F Solomon

Nancy J Brenner

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Radiolabeled cannabinoid-1 receptor modulators

The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Radiolabeled neurokinin-1 receptor antagonists

The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.

Radiolabeled neuropeptide Y Y5 receptor antagonists

The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.

Radiolabeled farnesyl-protein transferase inhibitors

F-18 radiolabeled neurokinin-1 receptor antagonists

Novel radiolabeled cholecystokinin-A (CCK-A) antagonists have been developed which, after intravenous injection, localize in the pancreas as a result of specific binding to CCK-A receptors. These tracers, when labeled with appropriate radiohalogens, are useful as commercial diagnostic imaging radiopharmaceuticals and radiotherapeutic drugs.

Gamma emitting, CCK-A antagonists for pancreatic imaging

Growing community of inventors

Holland, PA, United States of America

Raymond E Gibson